Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
HONG KONG - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13), a biopharmaceutical company, announced today the publication of its Form 20-F for the financial year that concluded on December 31, 2024. The report is publicly accessible and can be viewed on the London Stock Exchange (LON:LSEG) website and HUTCHMED’s official site.
The Form 20-F is a comprehensive financial statement required by the U.S. Securities and Exchange Commission for foreign companies listed on U.S. stock exchanges. This document provides detailed information about HUTCHMED’s financial performance, including audited financial statements, facilitating transparency for investors and stakeholders.
HUTCHMED specializes in the development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one of these treatments also approved in several international markets, including the United States, Europe, and Japan.
The availability of the Form 20-F provides investors with crucial insights into HUTCHMED’s financial health and operational progress over the past year. This release is part of the company’s commitment to maintaining open communication with its shareholders and the broader investment community.
The company’s investor and media relations contacts have been provided for further inquiries, along with the details of its nominated advisor and joint brokers.
This news is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.